Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

About this update from Lexeo Therapeutics, Inc.

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027 NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that key results from Phase I/II studies of LX2006 gene therapy in Friedreich ataxia (FA) have been published in the Journal of the American Medical Association (JAMA) Cardiology, linked here.JAMA Cardiology Publication The assessment of safety and exploratory efficacy parameters of LX2006 combines data from two independent studies: nine participants from a Weill Cornell Medicine study, funded by the National Heart, Lung, and Blood Institute, and eight participants treated in the SUNRISE-FA study carried out by Lexeo Therapeutics. The two studies included patients with early cardiac disease and patients with established structural cardiac disease. In both studies, the patients received a one-hour intravenous infusion of LX2006 gene therapy and were evaluated from 6 to 36 months. Three different doses were tested among three cohorts of patients. “These positive Phase I/II data demonstrate clinically meaningful improvements across both cardiac and neurologic measures of Friedreich ataxia and this publication in JAMA Cardiology further underscores the significance of these results and the potential of this therapy for individuals living with this devastating disease,” said Narinder Bhalla, M.D., Chief Medical Officer of Lexeo Therapeutics. “We are grateful to Weill Cornell Medicine and the study investigators for helping advance this program to the next stage of clinical development and are excited to initiate the pivotal SUNRISE-FA 2 study this month.” “The publication of these results in JAMA Cardiology represents a meaningful milestone for our research program. Friedreich ataxia cardiomyopathy remains a progressive and life-threatening condition with no approved cardiac-specific treatments, and these findings reinforce the potential of gene therapy to address the underlying cause of disease,” said Dr. Ronald G. Crystal, lead author, professor and chair of the Department of Genetic Medicine at Weill Cornell Me...

View stock analysis, news, and events for Lexeo Therapeutics, Inc.